Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Jounce Therapeutics

DB:21J
Snowflake Description

Flawless balance sheet with proven track record.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
21J
DB
$145M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The last earnings update was 39 days ago. More info.


Add to Portfolio Compare Print
  • Jounce Therapeutics has significant price volatility in the past 3 months.
21J Share Price and Events
7 Day Returns
-10.7%
DB:21J
-0.7%
DE Biotechs
-0.6%
DE Market
1 Year Returns
-33.6%
DB:21J
-13.2%
DE Biotechs
-20.9%
DE Market
21J Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Jounce Therapeutics (21J) -10.7% -6.4% -45.4% -33.6% -82.3% -
DE Biotechs -0.7% -8.2% -21% -13.2% 13.2% -11.8%
DE Market -0.6% -18.6% -26.2% -20.9% -25.8% -31.8%
1 Year Return vs Industry and Market
  • 21J underperformed the Biotechs industry which returned -13.2% over the past year.
  • 21J underperformed the Market in Germany which returned -20.9% over the past year.
Price Volatility
21J
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Jounce Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Jounce Therapeutics. This is due to cash flow or dividend data being unavailable. The share price is €3.82.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Jounce Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Jounce Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:21J PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $1.72
NasdaqGS:JNCE Share Price ** NasdaqGS (2020-04-03) in USD $4.26
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 40.67x
Germany Market PE Ratio Median Figure of 401 Publicly-Listed Companies 16.57x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Jounce Therapeutics.

DB:21J PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:JNCE Share Price ÷ EPS (both in USD)

= 4.26 ÷ 1.72

2.48x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Jounce Therapeutics is good value based on earnings compared to the Europe Biotechs industry average.
  • Jounce Therapeutics is good value based on earnings compared to the Germany market.
Price based on expected Growth
Does Jounce Therapeutics's expected growth come at a high price?
Raw Data
DB:21J PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 2.48x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts
-31.7%per year
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.62x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.17x

*Line of best fit is calculated by linear regression .

DB:21J PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 2.48x ÷ -31.7%

-0.08x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Jounce Therapeutics earnings are not expected to grow next year, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Jounce Therapeutics's assets?
Raw Data
DB:21J PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $5.17
NasdaqGS:JNCE Share Price * NasdaqGS (2020-04-03) in USD $4.26
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.33x
Germany Market PB Ratio Median Figure of 572 Publicly-Listed Companies 1.44x
DB:21J PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:JNCE Share Price ÷ Book Value per Share (both in USD)

= 4.26 ÷ 5.17

0.82x

* Primary Listing of Jounce Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Jounce Therapeutics is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Jounce Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Jounce Therapeutics has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Jounce Therapeutics expected to perform in the next 1 to 3 years based on estimates from 6 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-31.7%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Jounce Therapeutics expected to grow at an attractive rate?
  • Jounce Therapeutics's earnings are expected to decrease over the next 1-3 years, this is below the low risk savings rate of -0.4%.
Growth vs Market Checks
  • Jounce Therapeutics's earnings are expected to decrease over the next 1-3 years, this is below the Germany market average.
  • Jounce Therapeutics's revenues are expected to decrease over the next 1-3 years, this is below the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:21J Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:21J Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts -31.7%
DB:21J Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 6 Analysts -45.2%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 55.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 24%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:21J Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:21J Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 37 -69 -101 2
2023-12-31 26 -78 -102 2
2022-12-31 19 -64 -93 4
2021-12-31 34 -57 -88 5
2020-12-31 19 -58 -76 6
2020-04-06
DB:21J Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 148 -30 57
2019-09-30 168 -31 77
2019-06-30 63 -82 -29
2019-03-31 65 -66 -27
2018-12-31 65 -64 -27
2018-09-30 58 -68 -35
2018-06-30 62 -75 -31
2018-03-31 63 -95 -30
2017-12-31 72 -91 -17
2017-09-30 79 -79 -5
2017-06-30 78 161 -1
2017-03-31 57 174 -11

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Jounce Therapeutics's earnings are expected to decrease over the next 1-3 years, this is not considered high growth.
  • Jounce Therapeutics's revenue is expected to decrease over the next 1-3 years, this is not considered high growth.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:21J Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below

All data from Jounce Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:21J Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 -2.23 -1.32 -3.50 3.00
2023-12-31 -2.46 -1.98 -3.30 3.00
2022-12-31 -2.28 -1.30 -3.11 4.00
2021-12-31 -1.78 0.32 -2.93 5.00
2020-12-31 -2.13 -1.10 -2.88 6.00
2020-04-06
DB:21J Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 1.72
2019-09-30 2.35
2019-06-30 -0.88
2019-03-31 -0.82
2018-12-31 -0.84
2018-09-30 -1.07
2018-06-30 -0.96
2018-03-31 -0.93
2017-12-31 -0.57
2017-09-30 -0.23
2017-06-30 -0.07
2017-03-31 -1.41

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Jounce Therapeutics will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Jounce Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Jounce Therapeutics has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Jounce Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Jounce Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Jounce Therapeutics has delivered over 20% year on year earnings growth in the past 5 years.
  • Jounce Therapeutics has become profitable in the last year making the earnings growth rate difficult to compare to the 5-year average.
  • Jounce Therapeutics has become profitable in the last year making it difficult to compare the Europe Biotechs industry average.
Earnings and Revenue History
Jounce Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Jounce Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:21J Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 147.87 56.82 33.73 35.45
2019-09-30 167.97 77.45 33.42 35.16
2019-06-30 63.06 -29.05 33.43 34.30
2019-03-31 64.99 -26.73 32.61 33.77
2018-12-31 65.20 -27.38 32.17 33.16
2018-09-30 58.09 -34.70 31.46 34.07
2018-06-30 61.64 -31.15 30.35 34.93
2018-03-31 62.55 -29.86 30.30 34.45
2017-12-31 71.64 -17.24 29.19 31.69
2017-09-30 78.94 -5.21 26.50 28.76
2017-06-30 77.78 -0.99 23.22 24.88
2017-03-31 57.49 -10.61 21.19 25.32
2016-12-31 37.20 -23.14 16.76 19.26
2016-09-30 16.91 -38.01 14.91 29.03
2016-06-30 0.00 -48.79 13.68 15.60
2016-03-31 -43.11 9.36 11.48
2015-12-31 -37.50 8.27 15.77
2015-09-30 -27.56 7.93 2.13
2015-06-30 -22.25 6.52 14.10
2015-03-31 -17.60 6.33 12.08
2014-12-31 -12.95 4.97 9.00
2013-12-31 -13.01 5.12 5.86

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Jounce Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).
  • Jounce Therapeutics used its assets more efficiently than the Europe Biotechs industry average last year based on Return on Assets.
  • Jounce Therapeutics has become profitable over the past 3 years. This is considered to be a significant improvement in its use of capital (Return on Capital Employed).
X
Past performance checks
We assess Jounce Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Jounce Therapeutics has a total score of 4/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Jounce Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Jounce Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Jounce Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Jounce Therapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Jounce Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Jounce Therapeutics has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Jounce Therapeutics Company Filings, last reported 3 months ago.

DB:21J Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 174.59 0.00 168.84
2019-09-30 191.41 0.00 175.80
2019-06-30 90.06 0.00 152.02
2019-03-31 94.42 0.00 163.79
2018-12-31 104.13 0.00 189.87
2018-09-30 103.41 0.00 211.76
2018-06-30 108.50 0.00 232.71
2018-03-31 110.29 0.00 237.18
2017-12-31 167.11 0.00 235.65
2017-09-30 175.06 0.00 251.09
2017-06-30 175.51 0.00 270.80
2017-03-31 177.96 0.00 262.25
2016-12-31 69.95 0.00 149.26
2016-09-30 63.81 0.00 167.87
2016-06-30 21.84 0.00 21.29
2016-03-31 44.20 0.00 45.16
2015-12-31 44.20 0.00 45.16
2015-09-30 54.00 0.00 52.75
2015-06-30 62.32 0.00 61.07
2015-03-31 62.32 0.00 61.07
2014-12-31 -0.69 0.00 2.34
2013-12-31 5.12 0.00 2.95
  • Jounce Therapeutics has no debt.
  • Jounce Therapeutics has not taken on any debt in the past 5 years.
  • Jounce Therapeutics has no debt, it does not need to be covered by operating cash flow.
  • Jounce Therapeutics has no debt, therefore coverage of interest payments is not a concern.
X
Financial health checks
We assess Jounce Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Jounce Therapeutics has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Jounce Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Jounce Therapeutics dividends.
If you bought €2,000 of Jounce Therapeutics shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Jounce Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Jounce Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:21J Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 316 Stocks 3.9%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.7%
Germany Top 25% Dividend Yield 75th Percentile 4.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:21J Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2020-04-06

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Jounce Therapeutics has not reported any payouts.
  • Unable to verify if Jounce Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Jounce Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Jounce Therapeutics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Jounce Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Jounce Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Jounce Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Jounce Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Rich Murray
COMPENSATION $3,686,268
AGE 60
TENURE AS CEO 5.8 years
CEO Bio

Dr. Richard Murray, Ph.D., also known as Rich, has been the Chief Executive Officer, President and Director of Jounce Therapeutics, Inc., since July 10, 2014. Prior to joining Jounce, Dr. Murray serves as Director of Platelet BioGenesis, Inc. Dr. Murray served as senior vice president of biologics and vaccines research and development at Merck & Co., a global healthcare company, from 2009 to June 2014. Dr. Murray served as Executive Vice President of PDL Biopharma Inc. (Formerly, Protein Design Labs Inc.) from February 20, 2007 to September 5, 2008 and also served as its Chief Scientific and Technical Officer from September 2005 to September 5, 2008; Senior Vice President of Research from September 2005 to February 20, 2007 and Vice President-Research from April 2003 to April 2004. Dr. Murray oversaw PDL Biopharma Inc.'s antibody discovery, process sciences, manufacturing and preclinical development activities. Dr. Murray served as Chief Scientific Officer of PDL Biopharma, Inc. from April 2004 to August 2008. He served as Vice President of Research at Eos Biotechnology, where he was also a co-founder of Protein Design Labs Inc. He served in that role at Eos from February 1998 to April 2003 and was responsible for the discovery and transition of antibody-based therapeutic candidates from research to development. Prior to Eos, Dr. Murray was a Staff Scientist, then Senior Staff Scientist at DNAX Research Institute. Prior to joining Merck, Dr. Murray provided strategic and operational guidance to protein therapeutic biotech companies and served as an advisor to venture capital and life science investors. He served as a Director of PDL BioPharma Inc., since February 20, 2007. Dr. Murray holds a Ph.D. in microbiology and immunology from the University of North Carolina at Chapel Hill and a B.S. in microbiology from the University of Massachusetts, Amherst.

CEO Compensation
  • Rich's compensation has increased in line with Jounce Therapeutics recently becoming profitable.
  • Rich's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Jounce Therapeutics management team in years:

8.3
Average Tenure
60
Average Age
  • The average tenure for the Jounce Therapeutics management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Rich Murray

TITLE
President
COMPENSATION
$4M
AGE
60
TENURE
5.8 yrs

Kim Drapkin

TITLE
CFO & Treasurer
COMPENSATION
$2M
AGE
51
TENURE
4.7 yrs

Beth Trehu

TITLE
Chief Medical Officer
COMPENSATION
$2M
AGE
59
TENURE
4.4 yrs

Jim Allison

TITLE
TENURE
8.3 yrs

Tom Gajewski

TITLE
TENURE
8.3 yrs

Bob Schreiber

TITLE

Drew Pardoll

TITLE
TENURE
8.3 yrs

Pam Sharma

TITLE
TENURE
8.3 yrs

Louis Weiner

TITLE
AGE
67
TENURE
8.3 yrs

Steve Farrand

TITLE
Chief Technical Officer
AGE
62
TENURE
3.6 yrs
Board of Directors Tenure

Average tenure and age of the Jounce Therapeutics board of directors in years:

4.4
Average Tenure
60
Average Age
  • The tenure for the Jounce Therapeutics board of directors is about average.
Board of Directors

Perry Karsen

TITLE
Independent Chairman of the Board
COMPENSATION
$150K
AGE
64
TENURE
4 yrs

Rich Murray

TITLE
President
COMPENSATION
$4M
AGE
60
TENURE
5.8 yrs

John Higgons

TITLE
Independent Director
COMPENSATION
$117K
AGE
64
TENURE
4.4 yrs

Barbara Duncan

TITLE
Independent Director
COMPENSATION
$118K
AGE
54
TENURE
3.9 yrs

Cary Pfeffer

TITLE
Independent Director
COMPENSATION
$108K
AGE
57
TENURE
7.2 yrs

Bob Tepper

TITLE
Independent Director
COMPENSATION
$100K
AGE
63
TENURE
7.2 yrs

Bob Kamen

TITLE
Independent Director
COMPENSATION
$100K
AGE
75
TENURE
7.2 yrs

Luis Diaz

TITLE
Independent Director
COMPENSATION
$86K
AGE
48
TENURE
2.5 yrs

Rob Iannone

TITLE
Director
AGE
51
TENURE
0.3 yrs
Who owns this company?
Recent Insider Trading
  • Jounce Therapeutics individual insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
10. Jan 20 Sell Kimberlee Drapkin Individual 07. Jan 20 07. Jan 20 -2,624 €6.98 €-18,328
10. Jan 20 Sell Elizabeth Trehu Individual 07. Jan 20 07. Jan 20 -2,624 €6.98 €-18,328
10. Jan 20 Sell Richard Murray Individual 07. Jan 20 07. Jan 20 -7,150 €6.98 €-49,942
10. Jan 20 Sell Hugh Cole Individual 07. Jan 20 07. Jan 20 -2,624 €6.98 €-18,328
17. Aug 19 Sell Hugh Cole Individual 14. Aug 19 16. Aug 19 -2,336 €3.69 €-8,408
17. Aug 19 Sell Elizabeth Trehu Individual 14. Aug 19 16. Aug 19 -2,336 €3.69 €-8,408
17. Aug 19 Sell Kimberlee Drapkin Individual 14. Aug 19 16. Aug 19 -2,336 €3.69 €-8,408
X
Management checks
We assess Jounce Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Jounce Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company offers vopratelimab, a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors, which is in Phase II clinical trial for the treatment of PD-1/PD-L1 inhibitor patients with non-small cell lung cancer and urothelial cancer. It is also developing JTX-4014, a clinical-stage anti-PD-1 antibody for combination therapy; and JTX-1811, a monoclonal antibody designed to selectively deplete T regulatory cells in the tumor microenvironment that is in the IND-enabling phase. The company’s product candidate includes JTX-8064, an antibody that binds to leukocyte immunoglobulin like receptor B2, which is a cell surface receptor expressed on macrophages. Jounce Therapeutics, Inc. was incorporated in 2012 and is headquartered in Cambridge, Massachusetts.

Details
Name: Jounce Therapeutics, Inc.
21J
Exchange: DB
Founded: 2012
$134,446,036
34,049,091
Website: http://jouncetx.com
Address: Jounce Therapeutics, Inc.
780 Memorial Drive,
Cambridge,
Massachusetts, 02139,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS JNCE Common Stock Nasdaq Global Select US USD 27. Jan 2017
DB 21J Common Stock Deutsche Boerse AG DE EUR 27. Jan 2017
Number of employees
Current staff
Staff numbers
130
Jounce Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/06 00:37
End of day share price update: 2020/04/03 00:00
Last estimates confirmation: 2020/03/25
Last earnings filing: 2020/02/27
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.